US 12,377,087 B2
Compounds for the treatment of cancer
Sucheta Telang, Louisville, KY (US); Jason Chesney, Louisville, KY (US); and John O. Trent, Louisville, KY (US)
Assigned to UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC., Louisville, KY (US)
Filed by UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC., Louisville, KY (US)
Filed on Nov. 13, 2020, as Appl. No. 17/097,080.
Application 17/097,080 is a division of application No. 15/568,751, granted, now 10,881,654, previously published as PCT/US2016/028868, filed on Apr. 22, 2016.
Claims priority of provisional application 62/152,239, filed on Apr. 24, 2015.
Prior Publication US 2021/0145821 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 215/42 (2006.01); A61K 31/4545 (2006.01); A61K 31/47 (2006.01); A61K 31/4706 (2006.01); A61P 35/00 (2006.01); C07D 215/46 (2006.01)
CPC A61K 31/4706 (2013.01) [A61K 31/4545 (2013.01); A61K 31/47 (2013.01); A61P 35/00 (2018.01)] 19 Claims
 
1. A pharmaceutical composition comprising a compound of Formula (IV)

OG Complex Work Unit Chemistry
wherein:
n is 4-6;
R1 is carboxylic acid (—CO—OH), methyl sulfonamide (—NH—SO2—CH3), carboxylic acid methyl ester (—CO—OCH3), or tert-butyl carbamate (—NH—CO—OC(CH3)3);
R2 is hydrogen or C2-C5 alkyl;
R3 is C1-C5 alkoxy; and
wherein if R2 is C2-C5 alkyl and located on the nitrogen of the quinoline group, then the nitrogen has a positive charge; and
wherein when R1 is carboxylic acid or carboxylic acid methyl ester, then R2 is hydrogen;
and at least one pharmaceutical excipient.